Table 3.
Univariate analysis findings showing participant beliefs regarding the risks posed by their rheumatologic medicationsa
| Belief that medication increases risk of contracting COVID‐19 | Belief that medication increases severity of COVID‐19 | |||||
|---|---|---|---|---|---|---|
| % (no./total no.)median (range) | OR (95% CI) | P | % (no./total no.)median (range) | OR (95% CI) | P | |
| Age, years | 49.0 (19.00–82.00) | 0.98 (0.971–0.994) | 0.003 | 50.0 (19.00–82.00) | 0.98 (0.970–0.993) | 0.002 |
| Female | 41.3 (161/390) | 1.07 (0.709–1.604) | 0.758 | 53.6 (206/384) | 1.18 (0.787–1.757) | 0.430 |
| Disease duration, years | 7.0 (0.00–53.00) | 1.00 (0.986–1.021) | 0.704 | 7.0 (0.00–53.00) | 1.00 (0.982–1.017) | 0.958 |
| Disease control (0–100) | 52.0 (18.00–87.00) | 1.00 (0.988–1.002) | 0.177 | 75.0 (0.00–100.00) | 1.00 (0.990–1.004) | 0.456 |
| Medications | ||||||
| No medication | 25.2 (29/115) | 1.00 | 30.2 (35/115) | 1.00 | ||
| Prednisolone only | 37.0 (10/27) | 5.33 (1.183–24.042) | 0.029 | 46.2 (12/26) | 1.98 (0.834–4.721) | 0.122 |
| csDMARD monotherapy | 31.3 (43/137) | 7.06 (1.538–32.393) | 0.012 | 47.1 (64/135) | 2.06 (1.223–3.461) | 0.007 |
| Combination csDMARDs | 61.1 (44/72) | 4.65 (0.956–22.565) | 0.057 | 76.1 (54/71) | 7.35 (3.747–14.424) | <0.001 |
| csDMARD + prednisolone | 41.9 (18/43) | 4.27 (0.870–20.928) | 0.074 | 54.5 (24/44) | 2.78 (1.360–5.669) | 0.005 |
| csDMARDs + prednisolone | 51.2 (21/41) | 18.67 (3.232–107.817) | 0.001 | 53.7 (22/41) | 2.68 (1.360–5.669) | 0.008 |
| b/tsDMARD monotherapy | 60.6 (20/33) | 5.78 (1.128–29.605) | 0.035 | 63.6 (21/33) | 4.05 (1.797–9.127) | 0.001 |
| b/tsDMARD + csDMARD(s) or prednisolone | 45.2 (19/42) | 6.14 (1.318–28.592) | 0.021 | 65.9 (27/41) | 4.46 (2.092–9.520) | <0.001 |
| b/tsDMARD + csDMARD(s) + prednisolone | 73.7 (14/19) | 4.36 (0.740–25.744) | 0.104 | 85.0 (17/20) | 13.11 (3.611–47.633) | <0.001 |
| Prednisolone dose (mg) | 0.0 (0.00–37.50) | 1.04 (1.002–1.085) | 0.039 | 0.0 (0.00–37.50) | 1.03 (0.990–1.074) | 0.135 |
a
Data missing for patients with concern regarding contracting COVID‐19 (n = 21, 10 female and 11 male) and for concern regarding more severe COVID‐19 (n = 24, 16 female and 8 male). OR = odds ratio; 95% CI = 95% confidence interval; csDMARD = conventional synthetic disease‐modifying antirheumatic drug; b/tsDMARD = biologic or targeted synthetic DMARD.